BlackRock, Inc. filed a Schedule 13G with the SEC on October 27, 2026, disclosing a beneficial ownership position in Wave Life Sciences, Inc. (NASDAQ:WVE) as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficial ownership of 13,356,138 shares of Wave Life Sciences common stock.
  • Percent of class: The reported position represents 6.8% of Wave Life Sciences outstanding common stock.
  • Sole voting power: BlackRock disclosed sole voting power over 13,040,746 shares.
  • Sole dispositive power: BlackRock disclosed sole dispositive power over all 13,356,138 shares reported.
  • No shared power: Both shared voting power and shared dispositive power are reported as 0.
  • Event date: The date of the event requiring the filing is stated as September 30, 2026.

BlackRock's Schedule 13G Ownership Disclosure for Wave Life Sciences

According to the filing, BlackRock, Inc., organized in Delaware and headquartered at 50 Hudson Yards, New York, NY 10001, reported aggregate beneficial ownership of 13,356,138 shares of Wave Life Sciences, Inc. common stock (CUSIP 94352A104). The position is classified as representing 6.8% of the class. BlackRock is identified as a parent holding company or control person under the applicable filing rule. The filing notes that the reported securities are held by certain business units, collectively described as the "Reporting Business Units," and that the statement "does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units."

The filing specifies that BlackRock holds sole voting power over 13,040,746 shares and sole dispositive power over the full 13,356,138 shares, with no shared voting or dispositive power reported. Wave Life Sciences is listed with its principal executive offices at 733 Concord Avenue, Cambridge, Massachusetts 02138. The filing was signed by Spencer Fleming, Managing Director of BlackRock, Inc., on October 27, 2026.

Regarding the right to receive dividends or sale proceeds, the filing states that "various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Wave Life Sciences, Inc." but that "no one person's interest in the common stock of Wave Life Sciences, Inc. is more than five percent of the total outstanding common shares." The filing also certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

BlackRock, Inc. disclosed beneficial ownership of 13,356,138 shares of Wave Life Sciences common stock, equal to 6.8% of the class, with sole voting power over 13,040,746 shares and sole dispositive power over the full position, as of September 30, 2026.